Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-05-09
2006-05-09
Campell, Bruce R. (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
07041638
ABSTRACT:
A means and method for treating pulmonary fibrosis and vaginitis in animals is described. The compositions include surfactant lipids in a pharmaceutically acceptable carrier. Surfactant lipids have been found to suppress the synergistic effect of bleomycin and SP-A in enhancing proinflammatory cytokine production. Surfactant lipids are also effective in the prevention and treatment of pulmonary fibrosis resulting from exposure to inflammatory agents affecting cytokine production. Furthermore, surfactant lipids are effective in treating attenuating the effect of proinflammatory cytokine production in vaginitis.
REFERENCES:
patent: 4861756 (1989-08-01), Jackson
patent: 5407914 (1995-04-01), Cochrane et al.
patent: 5683982 (1997-11-01), McLean et al.
patent: 5827825 (1998-10-01), Takei et al.
patent: 5891844 (1999-04-01), Häfner
patent: 6013619 (2000-01-01), Cochrane et al.
patent: 6436970 (2002-08-01), Häfner et al.
patent: 2002/0010494 (2002-01-01), Policker et al.
patent: 2002/0072540 (2002-06-01), Larsson et al.
patent: 2003/0096975 (2003-05-01), Hostetter et al.
patent: 0733 645 (1996-09-01), None
patent: 0383 837 (1998-02-01), None
patent: 0590 006 (2002-09-01), None
patent: 10316587 (1998-12-01), None
patent: WO 95/32992 (1995-12-01), None
patent: WO 01/76619 (2001-10-01), None
Chen et al., Surfactant and corticosteroid effects on lung function in a rat model of acute lung injury, Crit Care Med Nov. 2001; 29(11):2169-75 (Abstract).
Hohlfeld et al., The role of pulmonary surfactant in obstructive airways disease, Eur Respir J Feb. 1997; 10(2):482-91 (Abstract).
Otsubo et al., Characterization of synthetic lung surfactant activity against proinflammatory cytokines in human monocytes, Biol Pharm Bull Mar. 2002; 25(3): 312-7 (Abstract).
Wu et al., Effect of surfactant on pulmonary expression of type IIA PLA(2) in an animal model of acute lung injury, Am J Physiol Lung Cell Mol Physiol Apr. 2002; 282(4):L743-50 (Abstract).
Huang et al., Combined SP-A-bleomycin effect on cytokines by THP-1 cells: impact of surfactant lipids on this effect, Am J Physiol Lung Cell Mol Physiol 283:L94-L102, 2002.
Floros Joanna
Lin Zhenwu
MacNeill Colin
Phelps David S.
Umstead Todd M.
Audet Maury
Campell Bruce R.
McKee Voorhees & Sease, P.L.C.
The Penn State Research Foundation
LandOfFree
Surfactant prevention of vaginitis and lung complications... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Surfactant prevention of vaginitis and lung complications..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Surfactant prevention of vaginitis and lung complications... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3612591